Abstract
Patients with well-differentiated neuroendocrine tumours of the gastrointestinal tract often present with metastases and hormonal symptoms. These patients can be palliated by interventional tumour reduction and medical treatment with somatostatin analogues; no effective chemotherapy is available. Radionuclide therapy via somatostatin receptors is one new therapeutic alternative. The recognition that neuroendocrine tumours express specific receptors for growth factors and chemokines, which are of importance for tumour growth, vascularization, and spread, may open the way for new therapeutic approaches. The signalling pathways in carcinoid tumours are incompletely explored. This review summarizes potential new treatment strategies from clinical and experimental studies, e.g. inhibition of angiogenesis, targeting of growth factors or their receptors by tyrosine kinase inhibitors, interference with specific cellular pathways (mTOR, PI3K, RAS/RAF, Notch), and also inhibition of the proteasome and histone deacetylation. Combining targeted therapy with chemotherapy, or using drugs to sensitize for radionuclide therapy, may enhance the treatment outcome.
Keywords: monoclonal antibody, growth factor receptor, Angiogenesis inhibition, multikinase inhibition, neuroendocrine tumour, radionuclide therapy, small molecule inhibitor, somatostatin receptor
Anti-Cancer Agents in Medicinal Chemistry
Title: New Medical Strategies for Midgut Carcinoids
Volume: 10 Issue: 3
Author(s): Ola Nilsson, Yvonne Arvidsson, Viktor Johanson, Eva Forssell-Aronsson and Hakan Ahlman
Affiliation:
Keywords: monoclonal antibody, growth factor receptor, Angiogenesis inhibition, multikinase inhibition, neuroendocrine tumour, radionuclide therapy, small molecule inhibitor, somatostatin receptor
Abstract: Patients with well-differentiated neuroendocrine tumours of the gastrointestinal tract often present with metastases and hormonal symptoms. These patients can be palliated by interventional tumour reduction and medical treatment with somatostatin analogues; no effective chemotherapy is available. Radionuclide therapy via somatostatin receptors is one new therapeutic alternative. The recognition that neuroendocrine tumours express specific receptors for growth factors and chemokines, which are of importance for tumour growth, vascularization, and spread, may open the way for new therapeutic approaches. The signalling pathways in carcinoid tumours are incompletely explored. This review summarizes potential new treatment strategies from clinical and experimental studies, e.g. inhibition of angiogenesis, targeting of growth factors or their receptors by tyrosine kinase inhibitors, interference with specific cellular pathways (mTOR, PI3K, RAS/RAF, Notch), and also inhibition of the proteasome and histone deacetylation. Combining targeted therapy with chemotherapy, or using drugs to sensitize for radionuclide therapy, may enhance the treatment outcome.
Export Options
About this article
Cite this article as:
Nilsson Ola, Arvidsson Yvonne, Johanson Viktor, Forssell-Aronsson Eva and Ahlman Hakan, New Medical Strategies for Midgut Carcinoids, Anti-Cancer Agents in Medicinal Chemistry 2010; 10 (3) . https://dx.doi.org/10.2174/1871520611009030250
DOI https://dx.doi.org/10.2174/1871520611009030250 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Update on Laser Photochemotherapy: An Alternative for Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry The Place of Somatostatin Analogs in the Diagnosis and Treatment of the Neuoroendocrine Glands Tumors
Recent Patents on Anti-Cancer Drug Discovery Molecular Imaging of Neuropsychiatry and Boron Neutron Capture Therapy in Neuro-oncology
Current Molecular Imaging (Discontinued) Indirect Production of No Carrier Added (NCA) <sup>177</sup>Lu from Irradiation of Enriched <sup>176</sup>Yb: Options for Ytterbium/Lutetium Separation
Current Radiopharmaceuticals Application of PET to the Diagnosis, Staging, and Treatment of Locally Advanced Non-small Cell Lung Cancer
Current Medical Imaging The Role of Neuroendocrine Cells in Prostate Cancer: A Comprehensive Review of Current Literature and Subsequent Rationale to Broaden and Integrate Current Treatment Modalities
Current Medicinal Chemistry Cell Surface Nucleolin as a Target for Anti-Cancer Therapies
Recent Patents on Anti-Cancer Drug Discovery Peptide-Receptor Ligands and Multivalent Approach
Anti-Cancer Agents in Medicinal Chemistry Neuro-endocrine Markers in Neoplasms. Diagnostic Interest and Future Prospects
Current Proteomics Anti-Inflammatory Drug Targeting in Asthma. Should Inhaled Corticosteroids Reach the Small Airways?
Current Drug Therapy Porphyrins as Radiosensitizing Agents for Solid Neoplasms
Current Pharmaceutical Design A Comprehensive Overview of Colon Cancer- A Grim Reaper of the 21st Century
Current Medicinal Chemistry MicroRNAs as Tools and Effectors for Patient Treatment in Gastrointestinal Carcinogenesis
Current Drug Targets Chromogranin A and the Endothelial Barrier Function
Current Medicinal Chemistry About a Long Lasting Primary Pleomorphic Adenoma of the Lung with a Misleading Pattern
Current Respiratory Medicine Reviews Clinical Development of Inhibitors of the Insulin-like Growth Factor Receptor in Oncology
Current Drug Targets Defining Pharmacokinetics for Individual Patient Dosimetry in Routine Radiopeptide and Radioimmunotherapy of Cancer: Australian Experience
Current Pharmaceutical Design α7 nAChR in Airway Respiratory Epithelial Cells
Current Drug Targets Current Protein-based Anti-angiogenic Therapeutics
Mini-Reviews in Medicinal Chemistry The Human L1 Element: A Potential Biomarker in Cancer Prognosis, Current Status and Future Directions
Current Molecular Medicine